The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

REGN gets FDA nod for Dupixent for a broader population for the indication of chronic rhinosinusitis with nasal polyps.

In a recent study investigators established that extended dupilumab therapy-up to three years-is highly effective in the ...

The safety profile of Dupixent in adolescents with moderate-to-severe asthma contributed to the FDA's decision.

The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...

Small nasal polyps can be harmless, but if a nasal polyp blocks the sinuses or airway, it can lead to infections, difficulty ...

If you have surgery to remove a nasal polyp, your healthcare provider might also prescribe a topical steroid to apply to the inside of your nose after surgery. This can help prevent a recurrence of ...

nasal polyp size and sense of smell, while also reducing the need for systemic corticosteroids or surgery at 24 weeks compared to placebo. The approval is also supported by pharmacokinetic data ...

nasal polyp size, sense of smell, and reduced the need for systemic corticosteroids or surgery at 24 weeks compared to placebo. Dupixent's safety profile in adolescents was consistent with that ...

GSK receives Japanese MHLW approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Thursday, August 29, 2024, 09:00 Hrs [IST] GSK plc announc ...

GSK plc (LSE/NYSE: GSK) has received approval from Japan's Ministry of Health, Labour and Welfare for Nucala (mepolizumab) to treat chronic rhinosinusitis with nasal polyps (CRSwNP) in adults who ...